Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose response study
- PMID: 2908306
- DOI: 10.2165/00003495-198800366-00015
Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose response study
Abstract
Carvedilol 12.5, 25 and 50 mg was administered once daily for 4 weeks to patients with mild to moderate hypertension. The purpose of the study was to investigate the antihypertensive action of carvedilol when administered once daily and to investigate the pharmacokinetics of carvedilol in patients with mild to moderate hypertension. Measurable decreases in blood pressure (BP) occurred within 1 hour after the first dose. Peak decreases in supine diastolic blood pressure (DBP) were 9.0 +/- 6.8, 15.5 +/- 6.7, 14.7 +/- 10.6 and 22.5 +/- 7.6mm Hg (+/- SD) for the placebo, 12.5, 25 and 50mg carvedilol groups, respectively, and occurred between 3 and 7 hours after the dose. Administration of carvedilol once daily for 4 weeks kept supine DBP below baseline levels for 24 hours. Trough supine DBP after 4 weeks of treatment were 0.6 +/- 6.5, 7.3 +/- 7.9, 8.8 +/- 7.4 and 12.1 +/- 3.8mm Hg (+/- SD) below baseline. Serum levels of carvedilol were proportional to the dose. Peak serum levels were 39 +/- 27, 75 +/- 38 and 161 +/- 131 mu/L for carvedilol 12.5, 25 and 50mg. The kinetics of carvedilol did not change with repeated administration. Carvedilol was well tolerated; 2 patients experienced dizziness associated with postural hypotension after administration of the 50mg dose. Carvedilol 12.5, 25 and 50mg effectively reduced BP for 24 hours when administered once daily.
Similar articles
-
Safety and efficacy of once-daily carvedilol vs twice-daily labetalol in mild to moderate hypertension.Eur J Clin Pharmacol. 1990;38 Suppl 2:S164-6. doi: 10.1007/BF01409489. Eur J Clin Pharmacol. 1990. PMID: 1974509 Clinical Trial.
-
Dose-effect relationship of carvedilol in essential hypertension. An open study.Drugs. 1988;36 Suppl 6:75-81. doi: 10.2165/00003495-198800366-00014. Drugs. 1988. PMID: 2908305
-
Response rate with respect to the blood pressure-lowering effect of the vasodilating and beta-blocking agent carvedilol.Drugs. 1988;36 Suppl 6:92-101. doi: 10.2165/00003495-198800366-00016. Drugs. 1988. PMID: 2908307 Clinical Trial.
-
Clinical experience with dual-acting drugs in hypertension.Clin Investig. 1992;70 Suppl 1:S39-42. doi: 10.1007/BF00207610. Clin Investig. 1992. PMID: 1350483 Review.
-
Antihypertensive profile of carvedilol.Clin Investig. 1992;70 Suppl 1:S43-52. doi: 10.1007/BF00207611. Clin Investig. 1992. PMID: 1350484 Review.
Cited by
-
Cardiovascular pharmacology of K2P17.1 (TASK-4, TALK-2) two-pore-domain K+ channels.Naunyn Schmiedebergs Arch Pharmacol. 2018 Oct;391(10):1119-1131. doi: 10.1007/s00210-018-1535-z. Epub 2018 Jul 14. Naunyn Schmiedebergs Arch Pharmacol. 2018. PMID: 30008082
-
Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension.Cochrane Database Syst Rev. 2015 Aug 26;2015(8):CD007449. doi: 10.1002/14651858.CD007449.pub2. Cochrane Database Syst Rev. 2015. PMID: 26306578 Free PMC article.
-
Clinical pharmacology of carvedilol.Clin Investig. 1992;70 Suppl 1:S27-36. doi: 10.1007/BF00207608. Clin Investig. 1992. PMID: 1350481 Clinical Trial.
-
Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.Drugs. 1997 Jul;54(1):161-85. doi: 10.2165/00003495-199754010-00015. Drugs. 1997. PMID: 9211087 Review.
-
A simple LC-MS/MS method for pharmacokinetic study of carvedilol and 4/-hydroxyphenyl carvedilol at a low dose.Res Pharm Sci. 2022 Apr 18;17(3):231-241. doi: 10.4103/1735-5362.343077. eCollection 2022 Jun. Res Pharm Sci. 2022. PMID: 35531138 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials